Navigation Links
Staccato in Medical News

Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009

...nience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine) and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing. Both product ca...

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...nsaction, Alexza licensed to Symphony Allegro its staccato loxapine program and its staccato alprazolam program. Since that time, Alexza has ... we plan to submit Alexza's first NDA for AZ-004, staccato loxapine, in the first quarter of 2010. Symphony...

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

...venience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine) and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing. Both product ca...

Peter MacCallum Cancer Centre Expands Cancer Research Efforts with Automation Tool from Caliper Life Sciences

... - Foundation Purchases Caliper's staccato System to Enable High Throughput Research Processe...urne, Victoria, Australia. PMCC is using Caliper's staccato automation system to perform oncology related lab ...form this type of large scale research without the staccato workstation from Caliper," said Dr. Kaylene Simpso...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

...venience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine) and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing. Both product ca...

Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status

...ary focus on the continued development of AZ-004 ( staccato loxapine). The restructuring included a workforc...dates Development Update AZ-004 ( staccato loxapine). Alexza is developing AZ-004 for the a...his product candidate. AZ-104 ( staccato loxapine). Alexza is developing AZ-104 to treat ...

Alexza's Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference

...venience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine), and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing, both product can...

Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D

...venience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine), and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing, both product can...

Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates

...ase 3 studies without a partner, and is continuing to seek partners for the staccato migraine product candidates, AZ-001 and AZ-104. -- AZ-104 (Staccato loxap...eatment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that all...

Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.

... Alexza's single-dose Staccato(R) device in Singapore. Alexza's single-dose staccato devices are used in a majority of its current product candidates, including...eatment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that all...
Staccato in Medical Technology

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...ary focus on the continued development of AZ-004 ( staccato loxapine). The restructuring included a workforc...oduct Candidates Development Update - AZ-004 ( staccato loxapine). Alexza is developing AZ-004 for the a...d of the third quarter of 2009. - AZ-104 ( staccato loxapine). Alexza is developing AZ-104 to treat ...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

...id onset of pharmacological action provided by our staccato system is well-suited for migraine pain relief in ... AZ-104 is the combination of Alexza's proprietary staccato system with loxapine, a drug belonging to the clas...ounds known as dopamine receptor antagonists. The staccato system technology is a hand-held, chemically-heate...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... AZ-004 is the combination of Alexza's proprietary staccato system with loxapine, a drug belonging to the clas... compounds known generally as antipsychotics. The staccato system is a hand-held, chemically-heated, single d...inical and other related development activities of staccato loxapine (AZ-004 and AZ-104) and Staccato alprazol...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

...lieve that the ability to provide loxapine via our staccato technology, thus combining a drug with a well-esta... AZ-004 is the combination of Alexza's proprietary staccato system with loxapine, a drug belonging to the clas...f compounds known generally as antipsychotics. The staccato system is a hand-held, chemically-heated, single d...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

...emained in the clinic. Alexza's original IND for staccato loxapine was filed with the Division of Neuropharm...nd the Division of Neurology Products, or DNP. The staccato loxapine IND was transferred to the DPP, as the AZ.... Alexza is responsible for the development of the staccato Electric Multiple Dose device and the Company has ...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... AZ-004 is the combination of Alexza's proprietary staccato system with loxapine, a drug belonging to the clas...f compounds known generally as antipsychotics. The staccato system is a hand-held, chemically-heated, single d...rmittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a cond...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

...development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is ...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...lting from inhaled loxapine administration via the staccato system have the potential to make AZ-004 a viable ... AZ-004 is the combination of Alexza's proprietary staccato system with loxapine, a drug belonging to the clas...ds known generally as atypical antipsychotics. The staccato system technology used in AZ-004 is a hand-held, c...

Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder

...ts receiving 1 mg AZ-002 and 20 patients receiving staccato placebo. The primary aim of the clinical trial was... in the double-blind phase of the study received a staccato device (randomized to either 1 mg AZ-002 or placeb...inical and other related development activities of staccato alprazolam (AZ-002) and Staccato loxapine (AZ-004 ...

Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting

...development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is ...
Staccato in Biological Technology

Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation & Analysis

- Caliper Addresses Key Bottlenecks in Quality by Design Initiative for Protein Therapeutics - HOPKINTON, Mass., June 29 Caliper Life Sciences, Inc. (Nasdaq: CALP ), a leading provider of tools and services for drug discovery and life sciences research, today launched the Staccato Protein W...

Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009

...venience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine) and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing. Both product ca...

Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference

...venience. Alexza's lead program is AZ-004 ( staccato loxapine) and is being developed for the acute tr...n end-of-Phase 2 meeting with the FDA for AZ-001 ( staccato prochlorperazine), and it has advanced AZ-104 ( staccato loxapine) into Phase 2b testing, both product can...

Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...rkets," Mr. King continued. "Alexza has made substantial progress with its staccato technology and product candidates over the past several years, but find our...atment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that all...

Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling

... LabChip GX system, which performs fast, automated 1-D electrophoretic separations of nucleic acid samples. Caliper also offers Sciclone, Twister, and staccato liquid handling and integrated system solutions for higher throughput and more advanced genomics applications, such as next generation sequencing libr...

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

...development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is ...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

...ct in North America. Alexza is responsible for the development of the staccato Electric Multiple Dose device, and the Company has the exclusive right...eatment of acute and intermittent conditions. The Company's technology, the staccato system, vaporizes unformulated drug to form a condensation aerosol that all...

Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore

...ccato(R) device in Singapore. Alexza's single-dose staccato devices are used in a majority of its current prod... strategy is the development of production for the staccato device-related plastic and electronics components ...acturing operations." "Alexza's technology and staccato device offer patients a new paradigm to rapid syst...

MiddleBrook Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference

...us disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has ...

MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results

...us disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has ...
Staccato in Biological Products

Staccato Mini-Workstations from Caliper Life Sciences

Description:... staccato Mini-Workstations provide fast and reliable automa...ics, proteomics and drug development laboratories. staccato Mini-Workstations offer the minimal amount of inst...sic liquid handling and material management tasks. staccato Mini-Workstations are controlled with either Calip...
Company:Caliper Life Sciences

Staccato Cell Station - Assay from Caliper Life Sciences

Description:... The staccato Application Series are a line of pre-integrated an... time on science and less on engineering. The staccato Cell Station - Assay is a remarkably compact syste...extensive factory and site acceptance testing, the staccato Cell Station-Assay is a standard product which is ...
Company:Caliper Life Sciences

CLARA Integration Software Version 2.3 from Caliper Life Sciences

Description:...ement and quality control. CLARA® is the standard software for staccato Systems and custom Allegro Modules allowing for the simple interface with more than 100 laboratory devices. It is designed to connect "islands of auto...
Company:Caliper Life Sciences

Staccato Automated Systems from Caliper Life Sciences

Description:... The staccato Series of systems provide fast and reliable scalab...ics, proteomics and drug development laboratories. staccato systems are available in three base configurations...Application Series and Custom Systems Series. All staccato Application Series systems use a revolutionary new...
Company:Caliper Life Sciences

Staccato iBLOX Modular Tables from Caliper Life Sciences

Description:... The staccato Series of systems provide fast and reliable scalab...ics, proteomics and drug development laboratories. staccato systems are available in three base configurations... Custom Systems Series. All staccato Application Series systems use a revolutionary new...
Company:Caliper Life Sciences

Staccato Custom Series from Caliper Life Sciences

Description:... staccato Custom Series Systems provide fast and reliable au...ics, proteomics and drug development laboratories. staccato Custom Series are built specifically to customer s...ions that are tailored to their individual needs. staccato Custom Systems are controlled with either Caliper'...
Company:Caliper Life Sciences

Staccato Sciclone ELISA Station from Caliper Life Sciences

Description:... The staccato Series of systems provide fast and reliable scalab...ics, proteomics and drug development laboratories. staccato systems are available in three base configurations... Application Series and Custom Systems Series. The staccato Sciclone ELISA Station is a remarkably compact sys...
Company:Caliper Life Sciences

More>>

Other Tags
(Date:7/11/2014)... Volunteers from Scientology Churches and Missions are ... education lectures, forums and conferences, information stands, sports events, ... world. , Drug abuse is an international epidemic. According ... of alcohol and illicit drugs costs more than $425 ... and healthcare. , In the face of statistics ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... 11, 2014 Utilizing the Keller Funnel, ... William Koenig, has topped a record number of complication-free ... performed over 400 successful procedures without the occurrence of ... well known across the country for his expertise with ... has long been the foundation for numerous studies and ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional ... (Regular, Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, ... 2019 ” defines and segments the global probiotics ... market value of probiotic products and ingredients. The ... for the global market with an analysis of ...
Breaking Medicine News(10 mins):Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
Other Contents